The maker of the intravenous antifungal medication Mycamine has settled a whistleblower action against it with the U.S. government and several states for $7.3 million.
The settlement agreement between defendant Astellas Pharma US Inc. and relator Frank Smith, the federal government and Medicaid-participating states was unsealed Wednesday. The complaint was filed in 2010 in the U.S. District Court for the Eastern District of Pennsylvania by Smith, who alleged violations of the False Claims Act against Astellas.
